A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 70 years of age - have alopecia areata - able to apply topical study medication

Exclusion Criteria:

- alopecia totalis - alopecia universalis

Conditions & Interventions

Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
alopecia areata

More Information

Description: This study is being done to evaluate the safety and tolerability of twice daily application of the study drug, ARQ-255 topical suspension 3% people with alopecia areata. There are 2 study drugs in this study: ARQ-255 topical suspension 3% and vehicle (placebo). Participants will be randomized (like drawing straws) to either ARQ-255 topical suspension 3% or vehicle to be applied twice daily for 12 weeks. A vehicle is a study treatment that looks like the test drug and is made from the same base products used to make ARQ-255 topical suspension 3%, but it does not contain any active study ingredients.
Study Contact: Gretchen Bellefeuille - belle116@umn.edu
Principal Investigator: Maria Hordinsky
IRB Number: SITE00001818